Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CCR4 | P51679 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030130 | 1.00 | NPBWR1 (0.53) | NPBWR1MCHR1CYP1A2SPHK1F2 | |
| SCHEMBL3148367 | 1.00 | NPBWR1 (0.53) | NPBWR1MCHR1CYP1A2SPHK1F2 | |
| SCHEMBL7814221 | 0.96 | NPBWR1 (0.58) | NPBWR1MCHR1SIGMAR1CD274PDCD1 | |
| SCHEMBL7814225 | 0.96 | NPBWR1 (0.58) | NPBWR1MCHR1SIGMAR1CD274PDCD1 | |
| Hydrochloric Acid SCHEMBL7618359 | 0.95 | NPBWR1 (0.57) | NPBWR1MCHR1F2CD274PDCD1 | |
| SCHEMBL7309417 | 0.88 | SPHK1 (0.63) | NPBWR1MCHR1SPHK1F2CD274 | |
| SCHEMBL6508602 | 0.87 | MAOB (0.65) | SPHK1CD274PDCD1 | |
| SCHEMBL6508605 | 0.87 | MAOB (0.65) | SPHK1CD274PDCD1 | |
| SCHEMBL1819248 | 0.87 | CYP1A2 (0.60) | MCHR1CYP1A2SPHK1CD274PDCD1 | |
| SCHEMBL1972076 | 0.87 | CYP1A2 (0.60) | MCHR1CYP1A2SPHK1CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191705-A1 | NON-CANONICAL INSULINS AND THEIR USES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES INC. | 2025-08-07 | — | — | US | disclosed |
| EP-4525919-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12214018-B2 | Glucose responsive insulins | PROTOMER TECHNOLOGIES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240374735-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-11-14 | — | — | US | disclosed |
| US-12139502-B2 | Aromatic boron-containing compounds and related insulin analogs | PROTOMER TECHNOLOGIES INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116054-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | NPBWR1 112/4885MCHR1 106/4885CYP1A2 4240/4885 |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | IAPP, GPR119, INSR | NPBWR1 160/4885MCHR1 1951/4885CYP1A2 4014/4885 |
| US-12214018-B2 | Glucose responsive insulins | GLP1R, GPR119, IAPP | NPBWR1 113/4885MCHR1 107/4885CYP1A2 4191/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | NPBWR1 148/4885MCHR1 2762/4885CYP1A2 2895/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | NPBWR1 3549/4885MCHR1 4812/4885CYP1A2 2416/4885 |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | GPR119, INSR, IAPP | NPBWR1 203/4885MCHR1 223/4885CYP1A2 1802/4885 |
| US-12139502-B2 | Aromatic boron-containing compounds and related insulin analogs | IAPP, GPR119, INSR | NPBWR1 160/4885MCHR1 1951/4885CYP1A2 4014/4885 |
| US-20240374735-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | IAPP, GPR119, BRCA1 | NPBWR1 73/4885MCHR1 86/4885CYP1A2 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.